IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
Immunotherapy for NSCLC: What's Next?
February 07, 2017 | Online

Overview

This presentation will provide an update on how immunotherapy has rapidly integrated into standard 1st and 2nd-Line and beyond treatment settings. We will also review and discuss:

  • the role of biomarker testing in clinical practice;
  • management of toxicity associated with immunotherapy;
  • immunotherapy treatment duration;
  • newer combinations of therapies;
  • and ongoing and planned pivotal trials.

What you should expect to learn

After attending this program, participants will be able to:

  • recognize ongoing and planned  pivotal clinical trials of immunotherapy;
  • identify patients eligible for clinical trial participation;
  • specify immunotherapy for a select subset of patients likely to benefit.

David Spigel, MD

Chief Scientific Officer
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, TN

&

Ramaswamy Govindan, MD - Program Chair

Co-Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine

Contact